 VBI Vaccines Inc NASDAQ: VBIV has announced that results from Phase 3 PROTECT trial of VBIs prophylactic 3-antigen hepatitis B HBV vaccine candidate in adults were published in The Lancet Infectious Diseases. The study was designed to compare the immunogenicity and safety of 10 μg of VBIs 3-antigen vaccine candidate to 20 μg of the single-antigen HBV vaccine, Engerix-B, made by GlaxoSmithKline Plc NYSE: GSK. 